{"id":65785,"date":"2022-01-17T12:07:46","date_gmt":"2022-01-17T12:07:46","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=85345"},"modified":"2022-01-17T12:07:46","modified_gmt":"2022-01-17T12:07:46","slug":"seegene-continues-to-support-israels-effort-to-manage-the-omicron-variant-with-timely-delivery-of-five-million-tests","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/seegene-continues-to-support-israels-effort-to-manage-the-omicron-variant-with-timely-delivery-of-five-million-tests\/","title":{"rendered":"Seegene Continues to Support Israel\u2019s Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests"},"content":{"rendered":"
\n

<\/b>Seegene to export COVID-19 test that detects COVID-19 and Omicron along with its Master Assay that distinguishes between COVID-19 and other respiratory viruses<\/p>\n<\/div>\n

\n
\n

SEOUL, South Korea, Jan. 17, 2022 \/PRNewswire\/ —\u00a0Seegene Inc. (KQ 096530), South Korea’s leading molecular diagnostics company, announced today that\u00a0it has delivered over five million COVID-19 tests to Israel to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 million diagnostic tests and associated consumables in December 2021, while additional 3.4 million tests are scheduled to be delivered in January.<\/p>\n

\"Logo\"<\/div>\n

Like much of the world, Israel started to experience a shortage of COVID-19 tests as Omicron was driving an unprecedented surge in cases. More seriously, the number of flu or ‘flurona’ patients\u00a0who may be co-infected with flu and COVID-19 seems to increase this winter. Seegene’s prompt delivery of COVID-19 tests is expected to cover approximately 57% of Israel’s total 9 million population and play a crucial role in controlling the potential ‘twindemic’ season.<\/p>\n

“We will continue to support countries in need of COVID-19 tests to improve global health,” said Dr. Jong-Yoon Chun, Seegene Founder, and CEO. “It is apparent that Seegene’s accurate COVID-19 tests screening all COVID 19 variants and syndromic tests with the respiratory essential panel are going to be a key to the global effort of returning to normal. Both tests will also help to manage lives with COVID-19 and other respiratory infections.”<\/p>\n

Seegene will send various products to Israel, including its Allplex\u2122 SARS-CoV-2 Master Assay and Allplex\u2122 SARS CoV-2 FluA\/FluB\/RSV Assay.<\/p>\n